Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Jade Biosciences, Inc. (JBIO) had Consolidated Net Income/Loss of $-127.41M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-100.14M |
|
-- |
|
-- |
|
$113.54M |
|
$-113.54M |
|
$-13.81M |
|
$-127.35M |
|
$-127.35M |
|
$-127.41M |
|
$-127.41M |
|
|
Consolidated Net Income/Loss |
$-127.41M |
$-127.41M |
|
$-113.54M |
|
$-114.30M |
|
31.36M |
|
31.36M |
|
$-3.19 |
|
$-3.19 |
|
| Balance Sheet Financials | |
$348.82M |
|
$0.17M |
|
$0.96M |
|
$349.78M |
|
$16.54M |
|
-- |
|
$0.72M |
|
$17.26M |
|
$332.52M |
|
$332.52M |
|
$332.52M |
|
49.32M |
|
| Cash Flow Statement Financials | |
$-94.69M |
|
$-247.01M |
|
$360.77M |
|
$69.39M |
|
$88.44M |
|
$19.05M |
|
$20.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-94.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-38.32% |
|
-38.32% |
|
-36.43% |
|
-38.32% |
|
$6.74 |
|
$-3.03 |
|
$-3.02 |
|